Cell And Gene Therapy Laboratory Services | Pharmaron

Cell and Gene Therapy Programs

Pharmaron offers comprehensive services to advance Cell and Gene Therapy (CGT) programs from discovery through commercialization consisting of:

Connect with a Scientific Expert

End-to-end support for Advanced Therapy Medicinal Products (ATMPs)
AAV vectors (multiple serotypes)
Viral and non-viral delivery platforms
Cell-based therapies
State-of-the-art CGT laboratories operating under GLP, GCP, GCLP, CLIA/IVDR and GMP standards for full global regulatory compliance
Regulatory submission expertise, including INDs and BLAs with FDA, EMA, NMPA, and other authorities worldwide
Clinical and commercial batch release services to streamline development and accelerate market access

Automated liquid handler pipette tip positioned over microplate for preclinical studies sample processing

Preclinical Studies

Preclinical studies that assess CGT product safety, biodistribution and IND readiness across pharmacology, toxicology and ophthalmology.

Scientist in safety goggles and mask inspecting a sample vial in a modern lab for CGT bioanalysis services

CGT Bioanalysis

End-to-end CGT bioanalysis from Pharmaron, covering PK, ADA, biodistribution and efficacy biomarker assessments across all development stages.

Gloved scientist operating QuantStudio 7 Flex qPCR touchscreen during a CGT analytical testing services experiment

Analytical Testing Services

Analytical testing services for CGT covering identity, purity, and potency, from IND through commercial release.

Scientist monitors automated lab equipment via computer interface in a gene therapy CDMO setting for high-throughput processing and analysis.

Gene Therapy CDMO

Scalable Gene Therapy CDMO services—from plasmid design to clinical-grade drug substance—with advanced cGMP manufacturing and analytics.

A smiling scientist in protective eyewear stands beside a microscope in a lab, representing CGT ophthalmology research and development.

Cell and Gene Therapy (CGT) Ophthalmology Services

Advancing CGT ophthalmology with ocular disease models and diverse ocular dose routes for translational preclinical evaluation.

Close-up of microscope objectives over specimen slides for CGT safety assessment and cell therapy product toxicology analysis

CGT Safety Assessment

Preclinical CGT safety assessment from Pharmaron, covering immunogenicity, biodistribution, viral shedding, and histopathology.